A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach[1].
Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options[2].
| Parameter | Value |
|---|---|
| NCT Number | NCT03887455 |
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Eisai Inc. |
| Enrollment | 1906 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2019-03-27 00:00:00 |
| Completion Date | 2029-06-30 00:00:00 |
| Last Updated | 2025-10-14 00:00:00 |
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[2:1].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[3].
The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[4].
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[5].
The trial is being conducted at multiple centers worldwide, including:
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:
The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[6].
Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that selectively binds to large, soluble amyloid-beta (Aβ) protofibrils — the highly toxic oligomeric species believed to be the primary drivers of synaptic dysfunction and neuronal death in Alzheimer's disease.
Binding Specificity:
Clearance Mechanism:
| Antibody | Target Species | Mechanism | Status |
|---|---|---|---|
| Lecanemab | Aβ protofibrils | ADCC, clearance | Approved |
| Donanemab | N3pY-Aβ | Plaque removal | Approved |
| Crenezumab | Oligomers/fibrils | Aggregation inhibitor | Discontinued |
| Gantenerumab | Aβ plaques | Microglial clearance | Discontinued |
The Phase 3 Clarity AD study (NCT03887455) met itsprimary endpoint:
| Endpoint | Lecanemab | Placebo | Difference | p-value |
|---|---|---|---|---|
| CDR-SB change (18 mo) | +1.21 | +1.66 | -0.45 | p < 0.001 |
| Measure | Lecanemab | Placebo | Difference | p-value |
|---|---|---|---|---|
| Amyloid PET (Centiloids) | -55.48 | +0.93 | -56.41 | p < 0.001 |
| ADAS-Cog14 | +3.79 | +5.23 | -1.44 | p = 0.0007 |
| ADCS-MCI-ADL | -3.64 | -5.90 | +2.26 | p = 0.0002 |
| CDR-SB ( Extension) | +1.85 | +2.71 | -0.86 | p < 0.001 |
| Adverse Event | Lecanemab (%) | Placebo (%) |
|---|---|---|
| Infusion reactions | 20.4% | 4.6% |
| ARIA-E (edema) | 12.5% | 1.5% |
| Headache | 11.2% | 9.8% |
| ARIA-H (hemorrhage) | 10.3% | 5.1% |
| URTI | 8.7% | 7.9% |
| Fall | 7.8% | 8.2% |
Novel therapeutic approaches for neurodegenerative diseases (2024). 2024. ↩︎
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23). 2023. ↩︎ ↩︎
Amyloid cascade hypothesis: time for a reappraisal (2023). 2023. ↩︎
Mechanism-driven clinical trials in neurodegeneration (2024). 2024. ↩︎
Clinical trial design in neurodegenerative disease (2023). 2023. ↩︎
Future of Alzheimer's disease clinical trials (2024). 2024. ↩︎